Repository logo
 
Publication

Effect of Empagliflozin Beyond Glycemic Control: Cardiovascular Benefit in Patients with Type 2 Diabetes and Established Cardiovascular Disease

2019Journal article Open access
Simple item page
dc.contributor.authorMonteiro, P
dc.contributor.authorAguiar, C
dc.contributor.authorMatos, P
dc.contributor.authorSilva-Nunes, J
dc.contributor.authorBirne, R
dc.contributor.authorBranco, P
dc.contributor.authorCalado, J
dc.contributor.authorMelo, M
dc.contributor.authorPolónia, J
dc.date.accessioned2021-02-05T16:45:08Z
dc.date.available2021-02-05T16:45:08Z
dc.date.issued2019
dc.description.abstractThe prevalence of type 2 diabetes (T2D) continues to increase, and its association with cardiovascular (CV) disease has led to the inclusion of CV endpoints in clinical trials on the treatment of T2D. This article explores the various trials already performed and under development in this field, with particular focus on the EMPA-REG OUTCOME trial. In this trial, empagliflozin, a sodium-glucose co-transporter 2 inhibitor, demonstrated a reduction in CV risk in patients with T2D and established CV disease, in addition to CV safety and a decrease in glycated hemoglobin. This represents a paradigm shift that has led to changes in the international guidelines for the treatment of T2D. These results were maintained in subsequent subgroup analysis for heart failure, chronic kidney disease and peripheral arterial disease, although there are many questions concerning the mechanisms involved in these effects, including whether they are hemodynamic, metabolic or due to decreased myocardial cytoplasmic sodium concentrations. With this reduction in risk for major CV events in patients with T2D, the EMPA-REG OUTCOME trial demonstrated CV protection from a hypoglycemic drug for the first time, and opened a new era in the treatment and management of T2D. This study has led to the development of ongoing trials that will establish which patients will benefit most from this therapy, particularly with regard to comorbidities.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRev Port Cardiol. 2019 Oct;38(10):721-735.pt_PT
dc.identifier.doi10.1016/j.repc.2019.02.008pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3563
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevier Españapt_PT
dc.subjectBenzhydryl Compoundspt_PT
dc.subjectBlood Glucosept_PT
dc.subjectGlucosidespt_PT
dc.subjectHumanspt_PT
dc.subjectSodium-Glucose Transporter 2 Inhibitorspt_PT
dc.subjectCardiovascular Diseasespt_PT
dc.subjectDiabetes Mellitus, Type 2pt_PT
dc.subjectHCC ENDpt_PT
dc.subjectHCC NEFpt_PT
dc.titleEffect of Empagliflozin Beyond Glycemic Control: Cardiovascular Benefit in Patients with Type 2 Diabetes and Established Cardiovascular Diseasept_PT
dc.title.alternativeEfeito da Empagliflozina para Além do Controlo Glicémico: Benefício Cardiovascular em Doentes com DMT2 e Doença Cardiovascular Estabelecidapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage735pt_PT
oaire.citation.issue10pt_PT
oaire.citation.startPage721pt_PT
oaire.citation.titleRevista Portuguesa de Cardiologiapt_PT
oaire.citation.volume38pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
RPC 2019 721.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Download

Collections

END - Artigos
NEF - Artigos